NCT00679601已完成2 期
An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Plasma concentration of AN2690 in plasma and the concentration of AN2690 in urine over time
研究概览
简要总结
The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.
详细描述
A single center, open-label, multiple-dose study design will be used. Planned enrollment is 20 subjects to complete 15. Subjects must have a clinical diagnosis of onychomycosis of each great toenail and a clinical diagnosis of onychomycosis of six of the remaining toenails.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥18 and ≤65
- •BMI between 18.5 and 35 inclusive
- •Moderate to severe onychomycosis involving ≥80% of both great toenails, as determined by visual inspection after the nail has been trimmed
- •Combined thickness of the nail plate and nail bed of each great toenail is >3mm
- •At least 6 additional toenails with a clinical diagnosis of onychomycosis
- •If a female of childbearing potential, must be using of a highly effective method of birth control or abstinence and be willing to remain on that same method of birth control throughout the study
- •Capable of understanding and signing the informed consent, and willing to comply with all requirements of the study
排除标准
- •History of allergy to any of the study drug or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure
- •Clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety
- •Diabetes mellitus requiring treatment other than diet and exercise
- •Willing to refrain from the use of nail cosmetics such as clear and or colored nail lacquers from the screening visit until the end of the study
- •Nursing, pregnant or planning to become pregnant during the study
- •Failure to complete the specified washout period(s) for the following topical:
- •Topical antifungal applied to the feet (does not include antifungals for treatment of T. pedis during the study): 4 weeks
- •Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks
- •Failure to complete the specified washout period(s) for the following systemic medications:
- •Corticosteroids (including intramuscular injections): 2 weeks
- •Antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophyte: 24 weeks
- •Systemic immunomodulators: 4 weeks
- •Received treatment of any type for cancer within the last 6 months
- •History of any significant internal disease
- •Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated
- •AIDS or AIDS related complex
- •History of street drug or alcohol abuse
- •Donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six-week period preceding study initiation
- •Donated plasma during the two week period preceding study initiation
- •Participated in any other trial of an investigational drug or device within 30 days prior to enrollment or participation in a research study concurrent with this study
- •Prior enrollment in a study using the study drug, AN2690
结局指标
主要结局
Plasma concentration of AN2690 in plasma and the concentration of AN2690 in urine over time
时间窗: Days 0, 1, 14, 15, and 28
次要结局
- Efficacy measures of linear toenail growth, fungal culture results, KOH results, and clear toenail growth(Days 0, 14, 28, and 42)
- Safety and tolerance assessed by application site reactions, adverse events, vital signs, physical examinations, and 12-lead EKG(Days 0-28, and 42)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)OnychomycosisNCT00680160Pfizer15
已完成
1 期
Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed ConditionHealthyNCT00939835Torrent Pharmaceuticals Limited
已完成
1 期
Study Evaluating Premarin and Bazedoxifene Potential InteractionPostmenopauseNCT00745173Wyeth is now a wholly owned subsidiary of Pfizer30
已完成
1 期
A Study of [14C]-LY3866288 in Healthy ParticipantsHealthyNCT06644378Eli Lilly and Company15
已完成
1 期
A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)Attention-Deficit Hyperactivity DisorderNCT01886469Ironshore Pharmaceuticals and Development, Inc22